CompletedNot Applicable

Maternal Serum Adropin in Placenta Accreta Spectrum

Turkey (Türkiye)84 participantsStarted 2024-05-15

Plain-language summary

Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion. Methods: This cross-sectional study included 84 singleton pregnancies at ≥34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal serum adropin levels are measured preoperatively using enzyme-linked immunosorbent assay. Demographic, obstetric, ultrasonographic, and intraoperative findings were recorded. Receiver operating characteristic (ROC) curve analysis is performed to assess the predictive performance of adropin for PAS.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pregnant women aged 18-45 years in the reproductive period * Singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS Exclusion Criteria: * Uterine anomalies, * Chronic systemic diseases, * Multiple pregnancies, * Obstetric complications such as preterm premature rupture of membranes, threatened preterm labor, fetuses followed for intrauterine growth restriction, and placental abruption.

What they're measuring

Blood serum Adropin levels

Timeframe: From 15.04.2024 to 01.04.2025

Trial details

NCT IDNCT07421180

SponsorAdana City Training and Research Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-04-01

View on ClinicalTrials.gov More Placenta Accreta Spectrum trials